electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
9.94
-0.15 (-1.49%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.

It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance.

In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions.

electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

electroCore, Inc.
electroCore logo
Country United States
Founded 2005
IPO Date Jun 22, 2018
Industry Medical Devices
Sector Healthcare
Employees 68
CEO Daniel Goldberger

Contact Details

Address:
200 Forge Way, Suite 205
Rockaway, New Jersey 07866
United States
Phone 973 290 0097
Website electrocore.com

Stock Details

Ticker Symbol ECOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001560258
CUSIP Number 28531P103
ISIN Number US28531P2020
Employer ID 20-3454976
SIC Code 3845

Key Executives

Name Position
Daniel S. Goldberger Chief Executive Officer and Director
Dr. Thomas J. Errico M.D. Founder and Independent Director
Joshua S. Lev Chief Financial Officer
Michael Romaniw Executive Vice President of Systems and Operations
Donald Melnikoff Senior Vice President of Engineering, Regulatory and Compliance
Mitch Deshon Vice President of Global Sales and Business Development
Michael Mansfield Vice President of Marketing
Carrie Kochek Senior Director of Human Resources
Dr. Peter S. Staats M.B.A., M.D. Chief Medical Officer
Manuel A. Marques Senior Vice President of Operations

Latest SEC Filings

Date Type Title
Nov 15, 2024 D Notice of Exempt Offering of Securities
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Sep 6, 2024 8-K Current Report
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report
Aug 2, 2024 D Notice of Exempt Offering of Securities
Jul 23, 2024 424B3 Prospectus
Jul 22, 2024 EFFECT Notice of Effectiveness
Jul 18, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933